Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

14 Approvals To Look Out For In Q3

Executive Summary

As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.

Advertisement

Related Content

Teva's CGRP Inhibitor Fails In Chronic Cluster Headaches, Continues In Episodic
New EU Approval Further Boost For Tagrisso As Threats Recede
Dova’s Doptelet Gets First-To-Market Edge In Thrombocytopenia, Ahead Of Shionogi
Teva Pushes CGRP Timeline Back To End Of 2018
Animals Rule: SIGA’s Smallpox Drug Tecovirimat Sails Through US FDA Panel
Agios' IDH Inhibitors Show Their Mettle At ASH
Another Antibiotic Success Story as Tetraphase's Eravacycline Meets Goal
FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch
Shire CEO Says Lanadelumab Results Vindicate Dyax Buy, M&A Strategy
Progenics On Way To The FDA With Second Product Offering Azedra

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel